MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Bruce E. Sands  ¹     Brian G. Feagan  ²     Theresa Hunter Gibble  ³     Kristina Traxler  ³     Nathan Morris  ³     Xingyuan Li  ³     Stefan Schreiber  ⁴     Vipul Jairath  ⁴     Alessandro Armuzzi  ^5    
1 Icahn School of Medicine at Mount Sinai, New York, United States
² Western University, London, Canada
³ Eli Lilly and Company, Indianapolis, United States
⁴ University Hospital Schleswig-Holstein, Kiel, Germany
⁵ Humanitas University, Milan, Italy

Session
Patient reported outcomes in IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)